Welcome to our dedicated page for MOSAIC IMMUNOENGINEERING news (Ticker: CPMV), a resource for investors and traders seeking the latest updates and insights on MOSAIC IMMUNOENGINEERING stock.
Mosaic ImmunoEngineering, Inc. is a biotechnology company focused on developing novel immunotherapies to treat and prevent cancer. Headquartered in Carlsbad, California, Mosaic aims to advance cancer therapies for areas of high unmet medical need. The company recently signed a binding term-sheet with Oncotelic Therapeutics, Inc. to acquire rights to certain clinical stage necroptosis cancer therapies. These therapies disrupt tumor blood flow, resulting in immunogenic tumor cell death and a robust anti-cancer immune response. Mosaic will issue Oncotelic shares of its common stock valued at $15.0 million, with additional milestones for up to $15.0 million in shares of common stock. The acquisition includes access to Oncotelic's proprietary AI technologies for identifying immunotherapy combinations. Mosaic's experienced team, with over 30 FDA and worldwide product approvals, will be responsible for advancing the technologies, focusing on areas like uveal melanoma and retinoblastoma.
Mosaic ImmunoEngineering, Inc. has agreed to acquire certain clinical necroptosis cancer therapy assets from Oncotelic Therapeutics, Inc. The acquisition includes cancer and ocular disease programs, regulatory and clinical packages, and access to Oncotelic's AI platform for identifying immunotherapy combinations. The deal involves issuing Oncotelic shares of Mosaic common stock valued at $15.0 million, with potential additional shares worth up to another $15.0 million based on milestones. The Mosaic team will be responsible for advancing the development of the technologies, with both companies working together to ensure a smooth transfer of assets. The transaction is subject to due diligence and shareholder approval.
Mosaic ImmunoEngineering, Inc. (OTCQB:CPMV) has announced the issuance of a new US patent for their lead immunotherapy candidate, MIE-101, which targets cancer treatment. This patent complements existing ones and notably covers methods for utilizing plant-derived cowpea mosaic virus (CPMV) for both human and veterinary cancer therapies. MIE-101 has shown robust preclinical antitumor activity, even in naturally occurring canine tumors. The company stated that these patents enhance their intellectual property portfolio, vital for advancing clinical development. Notably, the newly issued U.S. Patent No. 11,617,787 builds on previous patents, granting Mosaic exclusive rights to this innovative cancer treatment approach, which may include combination therapies with radiation and chemotherapy.
Mosaic ImmunoEngineering has secured two research grants totaling $4.3 million from the National Cancer Institute to advance the development of cowpea mosaic virus (CPMV) as an immuno-oncology candidate. One grant focuses on optimizing large-scale production methods for human clinical trials, while the other targets CPMV as a platform technology. The funding enhances studies on the efficacy of MIE-101, the company's lead candidate, currently in late-stage preclinical development. Over $25 million in grants has been awarded for CPMV research.
Mosaic ImmunoEngineering received two research grants totaling $4.3 million from the National Cancer Institute to advance the study of cowpea mosaic virus (CPMV) as an immuno-oncology candidate. One grant will focus on optimizing large-scale production methods and regulatory studies for clinical development, while the other will develop CPMV as a platform technology. This funding contributes to over $25 million awarded to academic collaborators studying CPMV's potential against cancer. The company's lead candidate, MIE-101, is in late-stage preclinical development.
Mosaic ImmunoEngineering has signed an exclusive worldwide license agreement with Case Western Reserve University, granting rights to develop cancer treatment technologies using the cowpea mosaic virus (CPMV). This licensed technology is central to Mosaic's lead immunotherapy candidate, MIE-101, which shows promise in stimulating immune responses against various cancers. The agreement includes milestone payments and royalties on product sales. Mosaic aims to advance MIE-101, which has demonstrated effectiveness in preclinical studies.
Mosaic ImmunoEngineering's research reveals that inactivated Cowpea Mosaic Virus (inCPMV) combined with OX40 agonist antibodies elicits strong anti-tumor immunity, controlling tumor progression in a melanoma mouse model. The study, published in Molecular Pharmaceuticals, indicates that 70% of subjects survived for over 100 days without recurrence. This finding supports the potential of their lead candidate, MIE-101, to enhance responses to existing cancer therapies, addressing significant unmet medical needs in patient treatment.
Mosaic ImmunoEngineering Inc. (OTCQB:CPMV) presented promising data on its lead immuno-oncology candidate, MIE-101, derived from the cowpea mosaic virus (CPMV), at the Materials in the Anthropocene Conference. The research highlights CPMV's ability to stimulate robust immune responses against multiple cancer types, showing durable antitumor activity in preclinical studies. The nanoparticle technology is effective for both human and canine cancers, showcasing significant potential for future clinical trials. Mosaic aims to advance MIE-101 through dual development pathways.
Mosaic ImmunoEngineering announced a presentation by CEO Steven King at the 23rd Annual SoCalBio Conference on October 21, 2021, focusing on MIE-101, its immuno-oncology candidate derived from the cowpea mosaic virus (CPMV). MIE-101 has been shown to activate immune responses against various cancer types, demonstrating potential for both single-agent use and in combination with other therapies. The conference serves as a platform for showcasing innovations in the biotech sector and facilitating partnerships.
Mosaic ImmunoEngineering (OTCQB:CPMV) presented its innovative COVID-19 vaccine candidates at the World Molecular Imaging Congress on October 8, 2021. The candidates generate antibodies that neutralize SARS-CoV-2, offering a potential solution for areas lacking traditional vaccine infrastructure. Utilizing a plant virus-based protein nanoparticle, the vaccines can be stored at room temperature and administered via a single-dose implant. This technology aims to provide better protection against emerging variants, with preclinical studies demonstrating strong immune responses against COVID-19.
Mosaic ImmunoEngineering (OTCQB:CPMV) has licensed new rights to enhance its protein nanoparticle platform for cancer treatment. This technology, sourced from UC San Diego, utilizes plant virus-derived nanoparticles loaded with immuno-stimulatory molecules, potentially improving immune response against tumors. The development aims to complement Mosaic’s existing immunotherapy strategies, particularly its lead candidate, MIE-101, which has shown promise in preclinical studies across various cancers. The company seeks to explore commercial opportunities in both human and veterinary applications.
FAQ
What is the current stock price of MOSAIC IMMUNOENGINEERING (CPMV)?
What is the market cap of MOSAIC IMMUNOENGINEERING (CPMV)?
What is Mosaic ImmunoEngineering, Inc. focused on?
What recent partnership did Mosaic announce?
How do the necroptosis cancer therapies work?
What milestones are included in the acquisition agreement with Oncotelic?
What areas of high unmet medical need is Mosaic focusing on?
